ADDF Diagnostics Accelerator Funding for FTD Biomarker Development supports researchers developing biomarkers for frontotemporal degeneration to advance diagnosis and treatment.
Accelerating Drug Discovery for Frontotemporal Degeneration supports researchers and clinicians developing small molecules and biologics to advance disease-modifying treatments for frontotemporal dementia.
Accelerating Drug Discovery for FTD supports investigators developing small molecule and biologic drugs through lead optimization and animal-model testing to advance disease-modifying treatments for FTD.
The Treat FTD Fund from the Alzheimer's Drug Discovery Foundation supports early-stage research and clinical trials to develop new therapies and biomarkers for frontotemporal degeneration.
ADDF-Harrington supports academic investigators with research funding and drug development expertise to advance medicines for Alzheimer’s disease, related dementias, and aging-related cognitive decline.
The Treat FTD Fund supports early-stage clinical trials for innovative FTD treatments, prioritizing biomarker integration and novel trial designs, funded by The Association for Frontotemporal Degeneration.